Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test

Brief Report: Tepotinib as a Treatment Option in MET Exon 14 Skipping-Positive Lung Cancers—Investigating Discordance Between ArcherMET and the Oncomine Dx Target Test

Introduction: NSCLC is a leading cause of cancer-related mortality worldwide. Specific genetic alterations, such as MET exon 14 (METex14) skipping, have been identified in NSCLC, allowing targeted therapy. Tepotinib, a highly selective MET inhibitor, has displayed promise in patients with advanced N...

Full description

Bibliographic Details
Main Authors: Yoshihiro Miyashita, MD, Yosuke Hirotsu, PhD, Yuki Nagakubo, MS, Hiroaki Kobayashi, MD, Makoto Kawaguchi, MD, Koki Hata, MD, Ryota Saito, MD, Yumiko Kakizaki, MD, Toshiharu Tsutsui, PhD, Toshio Oyama, MD, Masao Omata, MD
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
MET
Tepotinib
Oncomine
Archer
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000493

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324000493

Similar Items